Clyde Biosciences receives funding boosts
Morisons has helped secure £2m investment for Glasgow based Clyde Biosciences.
Founded by a team of academics from the University of Glasgow, Clyde Biosciences has developed technology capable of providing unique insights into the early stage development of drug effectiveness and toxicity providing vital benefits for drug screening and a better understanding of how a drug works.
Epidarex Capital, along with the Scottish Investment Bank and Glasgow University Holdings, provided the funding which will enable the company to develop its client base.
Andy Sloane, Business Team Partner said, “Clyde Biosciences is a spin out company from The University of Glasgow and its technologies using human stem cells are pioneering in the advancement of drug research and development as they provide direct results of the effects of drugs on human tissue. The company has a great team and now specialised and supportive investors and it’s exciting to see a home grown business take up position in a global market on that platform.”< Back